The Global COPD Drug Delivery Device Market Size accounted for USD 9.2 Billion in 2021 and is estimated to garner a market size of USD 13.7 Billion by 2030 rising at a CAGR of 4.7% from 2022 to 2030. The rising prevalence of chronic respiratory diseases around the world is the primary factor driving the COPD drug delivery device market value. In addition, rapid advancement in medical devices is another factor supporting market growth. Furthermore, players focus on development of smart/digital inhalers is one of the prominent COPR drug delivery device market trends that is strengthening the industry growth during the projected timeframe from 2022 to 2030.

COPD Drug Delivery Devices Market Report Key Highlights

• Global COPD drug delivery device market revenue is estimated to reach USD 13.7 Billion by 2030 with a CAGR of 4.7% from 2022 to 2030
• According to the World Health Organization, Chronic obstructive pulmonary disease (COPD) caused 3.23 million world deaths in 2019
• North America COPD drug delivery device market conquered more than 40% regional shares in 2021
• Asia-Pacific COPD drug delivery device market will attain a notable CAGR from 2022 to 2030
• Based on product segment, inhalers acquired more than 75% of the total market share in 2021
• Growing development of innovative products drives the COPD drug delivery device market growth in coming years

According to the U.S. Department of Health and Human Services, currently, more than 25 million people in the United States have asthma and approximately 14.8 million adults have been diagnosed with COPD. In addition, the government of developed and developing countries is spending high on the development of the healthcare sector and increasing public-private partnerships for R&D activities are factors expected to support the chronic obstructive pulmonary disease drug delivery device market growth.

Global COPD Drug Delivery Device Market Dynamics

Market Drivers

• Increasing number of COPD population
• Rising incidences of chronic disorders
• Surging base of elderly population
• Rapid growth in respiratory disorders

Market Restraints

• Regulatory issues related to COPD drugs
• High pricing pressures

Market Opportunities

• Significant opportunities from emerging economies
• Introduction to innovative drug devices

COPD Drug Delivery Device Market Report Coverage

Market	COPD Drug Delivery Device Market
COPD Drug Delivery Device Market Size 2021	USD 9.2 Billion
COPD Drug Delivery Device Market Forecast 2030	USD 13.7 Billion
COPD Drug Delivery Device Market CAGR During 2022 - 2030	4.7%
COPD Drug Delivery Device Market Analysis Period	2018 - 2030
COPD Drug Delivery Device Market Base Year	2021
COPD Drug Delivery Device Market Forecast Data	2022 - 2030
Segments Covered	By Product, By Type, By Distribution Channel, By End-Use, And By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries, Merck & Co., Inc., Cipla Inc., Sunovion Pharmaceuticals, Inc., Koninklijke Philips N.V., AstraZeneca, PARI GmbH, and Omron Corporation.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

COPD Drug Delivery Device Market Insights

The rising geriatric population in developing countries and demand for minimal invasive drug delivery solution is expected to impact positively on the growth of the target market.

However, factors such as stringent government regulation related to product approval and high cost associated with product and R&D activities are expected to hamper the growth of the global COPD drug delivery device market. In addition, the lack of reimbursement policies in developing countries is expected to challenge the growth of the target market.

Technological advancements by major players and an inclination toward tracking the untapped market in emerging economies are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, players focusing on the online channel in order to enhance the customer reach are expected to support the revenue growth of the target market.

COPD Drug Delivery Device Market Segmentation

The worldwide COPD drug delivery device market is split based on product, type, distribution channel, end-use, and geography.

COPD Drug Delivery Device Market By Product

• Inhalers
• Nebulizers

According to our COPD drug delivery device industry analysis, the product segment is bifurcated into inhalers and nebulizers. The inhaler segment is expected to account for a significant revenue share in the target market. The high growth in the segment is credited to the increasing product development activities by major players. However, the nebulizers sub-segment is anticipated to achieve a substantial growth rate in the coming years. Increasing technological advancements and the preference of the population to purchase a portable nebulizer are supporting the segmental growth.

COPD Drug Delivery Device Market By Type

• Manual Devices
• Digital Devices

According to our COPD drug delivery device market forecast, manual devices are expected to generate over 75% of the total market share from 2022 to 2030. On the other hand, digital devices are expected to witness faster growth in the target market. The rising digitalization in the healthcare industry, growth in healthcare IT, increasing adoption of digitally advanced devices, and precise readings of patients' vital signs are some of the aspects that are supporting the digital devices in the COPD drug delivery device industry.

COPD Drug Delivery Device Market By Distribution Channel

• Online
• Offline

The offline distribution channel is bifurcated into hospital pharmacies and retail pharmacies. In 2021, the online pharmacy distribution channel dominated the COPD drug delivery device market with utmost shares and is expected to continue its dominance throughout the forecasted years from 2022 to 2030. On the other hand, the online distribution channel sub-segment is likely to gain significant traction in the coming years owing to the consumer's shift towards online pharmacies.

COPD Drug Delivery Device Market By End-Use

• Hospitals
• Clinics
• Homecare Settings

Based on end-use, hospitals currently hold a majority of the COPD drug delivery device market value. The presence of healthcare professionals such as doctors, nurses, etc., and the inclination of patients towards hospitals due to the provision of enhanced treatment are the two key factors supporting the hospital's end-use segment. Besides, homecare settings would grow with an impressive growth rate from 2022 to 2030 due to the increased purchase power of consumers and rising preference for homecare treatments due to COVID-19.

COPD Drug Delivery Device Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa

As per CDC Data, COPD is Diagnosed among 16 Million Americans Till Date

The market in North America is expected to account for a significant revenue share owing to the increasing number of outpatients in hospitals suffering from COPD. In addition, the presence of a large number of players operating in the country, high investment in R&D activities, along with the introduction of innovative solutions are factors expected to support the growth of the regional market. Major players' focus on enhancing their business presence through partnerships and agreements is expected to further boost the growth of the target market.

COPD Drug Delivery Device Market Players

The global COPD drug delivery device companies profiled in the report include Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries, Merck & Co., Inc., Cipla Inc., Sunovion Pharmaceuticals, Inc., Koninklijke Philips N.V., AstraZeneca, PARI GmbH, and Omron Corporation.

Major players are focused on enhancing their business presence in order to increase the customer base and increase profit which is expected to augment the growth of the target market.

In 2018, Koninklijke Philips N.V. launched InnoSpire Go smallest and lightest portable hand-held nebulizer that provides portable, fast, and effective medication delivery. This is expected to help the company to enhance its customer base.

In 2020, AireHealth acquired BreathResearch’s research and patents, which include work on machine learning analytics for respiratory condition tracking. This is expected to help the company to enhance its product portfolio.

In 2019, Hill-Rom, Inc., a company focused on making hospital beds, furniture, other health care equipment, and medical technology systems acquired Breathe Technologies, a global provider of wearable ventilators for people with lung conditions such as chronic obstructive pulmonary disease. This is expected to help the company to enhance its customer base.

In 2019, Cipla Limited which primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, and depression; other medical conditions launched Niveoli for use in respiratory inhalation therapy. This is expected to help the company to enhance its customer base.

In 2020, Glenmark Pharmaceuticals a generic drug and active pharmaceutical ingredient manufacturer launched a triple therapy inhaler in the India market for patients suffering from chronic COPD. This is expected to help the company to strengthen its position in the global market.

TABLE OF CONTENT